Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.

@article{Brenner2013PhaseID,
  title={Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.},
  author={Andrew J. Brenner and Yael C Cohen and Eyal Breitbart and Livnat Bangio and John Sarantopoulos and Francis J Giles and Ernest C. Borden and Dror Harats and Pierre L Triozzi},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 14},
  pages={3996-4007}
}
PURPOSE VB-111 is an antiangiogenic agent consisting of a nonreplicating adenovirus vector (Ad-5) with a modified murine pre-proendothelin promoter leading to apoptosis of tumor vasculature by expressing a Fas-chimera transgene in angiogenic endothelial cells. In a phase I dose-escalation study, pharmacokinetics, pharmacodynamics, safety, and efficacy of a… CONTINUE READING